Chemical Biology and Drug Design

JUNE 21, 2025

RLX-2 alleviates hyperoxia-induced acute lung injury in neonatal rats. RLX-2 reduces inflammation and oxidative stress in neonatal rat lung tissues. RLX-2 inhibits TLR4-MyD88-NF-κB signaling in hyperoxia-induced lung injury. SIRT1 activation mediates RLX-2's anti-inflammatory and anti-oxidative effects. ABSTRACT Hyperoxia-induced acute lung injury (ALI) in neonates is driven by oxidative stress and inflammation.

Research

KIF1A

JUNE 21, 2025

Dear KIF1A.ORG Community, As the middle of the year rolls in, we’re filled with excitement and anticipation for our upcoming KAND Family & Scientific Engagement Conference happening July 25–26, 2025 in Boston, Massachusetts ! This event is one of our most important opportunities to bring together patients, families, researchers, clinicians, and advocates—all united in our mission to discover treatments and a cure for KAND.

Therapies

Drugs.com

JUNE 21, 2025

SATURDAY, June 21, 2025 — The first two years of a baby’s life are critical for brain development, and how the brain grows during that time may help predict future learning, behavior and health. That’s according to experts at.

Science Daily: Pharmacology News

JUNE 21, 2025

Quantum computing just got a significant boost thanks to researchers at the University of Osaka, who developed a much more efficient way to create "magic states"—a key component for fault-tolerant quantum computers. By pioneering a low-level, or "level-zero," distillation method, they dramatically reduced the number of qubits and computational resources needed, overcoming one of the biggest obstacles: quantum noise.

Research

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

New Drug Approvals

JUNE 21, 2025

Modoflaner ‘ Molecular Weight 715.23 Formula C 23 H 10 F 12 IN 3 O 2 CAS No. 1331922-53-2 6-fluoro- N -[2-fluoro-3-[[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2-iodo-6-(trifluoromethyl)phenyl]carbamoyl]phenyl]pyridine-3-carboxamide 3-Pyridinecarboxamide, 6-fluoro-N-(2-fluoro-3-(((2-iodo-4-(1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl)-6-(trifluoromethyl)phenyl)amino)carbonyl)phenyl)- 6-fluoro-N-[2-fluoro-3-[[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2-iodo-6-(trifluoromethyl)phenyl]carbamoyl

Regulations

Science Daily: Pharmacology News

JUNE 21, 2025

Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's multibillion-dollar heart drug. A new BMJ investigation reveals data discrepancies, missing lab readings, and questions about the integrity of the trial process. Notably, key results reported in a major cardiology journal were inaccurately presented, and some study contributors were omitted or denied involvement.

FDA

Science Daily: Pharmacology News

JUNE 21, 2025

A stunning breakthrough in solar physics reveals ultra-fine magnetic structures on the Sun's surface, thanks to the NSF's Inouye Solar Telescope. Researchers captured never-before-seen bright and dark stripes—called striations—within solar granules. These features behave like magnetic curtains rippling across the Sun, reshaping our understanding of magnetic field dynamics at microscopic scales.

Research